Frontiers in cardiovascular medicine
Urolithin A has antiplatelet effects in contrast to its glucuronide, urolithin B, and isourolithin A
By Soloviova A, Hrubša M, García CJ and 3 others.
Abstract
Introduction
Consumption of dietary ellagitannins has been suggested to have protective effects against cardiovascular disease, likely due to the colonic formation of urolithins and their subsequent systemic absorption. Urolithins have been previously shown to possess vasodilatory and anti-inflammatory properties. In this study, it was examined whether urolithins (urolithin A, B, and isourolithin A) and two of their glucuronides (urolithin A 3-glucuronide, isourolithin A 3-glucuronide) can block platelet aggregation in humans.
Methods
Seventeen healthy volunteers were included in this study. For the assessment of platelet aggregation, whole blood impedance aggregometry was utilized. Coagulation was examined using a semi-automatic coagulometer with mechanical clot detection. Acute toxicity was evaluated with a rat red blood cell lysis assay. For mechanistic studies, an ELISA-based commercial kit was used.
